

## **Product datasheet for TL300798V**

#### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

### TSC22D3 Human shRNA Lentiviral Particle (Locus ID 1831)

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

Product Name: TSC22D3 Human shRNA Lentiviral Particle (Locus ID 1831)

Locus ID: 183°

Synonyms: DIP; DSIPI; GILZ; TSC-22R

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: TSC22D3 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1

scramble control), 0.5 ml each, >10^7 TU/ml.

**RefSeq:** NM 001015881, NM 001318468, NM 001318470, NM 004089, NM 198057, NM 004089.1,

NM 004089.2, NM 004089.3, NM 198057.1, NM 198057.2, NM 001015881.1, BC072446,

BC072446.1, BC018148, BM047061, NM 198057.3, NM 004089.4

UniProt ID: Q99576

**Summary:** This gene encodes the anti-inflammatory protein glucocorticoid (GC)-induced leucine zipper.

Expression of this gene stimulated by glucocorticoids and interleukin 10 and it appears to play a key role in the anti-inflammatory and immunosuppressive effects of this steroid. This protein has also been shown to inhibit pro-inflammatory molecules including nuclear factor κB. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Jan

2016]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).